The future use of combination therapies to avoid viral resistance and achieve sustained response in chronic hepatitis C

Ira M. Jacobson, John G. McHutchison, Mark Sulkowski

Research output: Contribution to journalReview articlepeer-review

Abstract

The morbidity and mortality associated with chronic hepatitis C infection has been dramatically alleviated with the introduction of the current standard of therapy, pegylated interferon in combination with ribavirin. However, a significant number of infected patients do not respond adequately to treatment, or are unable to receive this therapy due to adverse effects. An increased understanding of the biology of the hepatitis C virus has helped to further the discovery and clinical development of a novel class of targeted antiviral agents with activity against hepatitis C-specific proteins. Recent studies have focused on the mutational resistance the hepatitis C virus displays against these new agents. The main strategy to overcome this resistance is combination therapy, a modality that has become the focus and future goal of therapy to achieve a sustained virologic response in patients with chronic hepatitis C.

Original languageEnglish (US)
Pages (from-to)2-10
Number of pages9
JournalGastroenterology and Hepatology
Volume3
Issue number12
StatePublished - Dec 1 2007

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'The future use of combination therapies to avoid viral resistance and achieve sustained response in chronic hepatitis C'. Together they form a unique fingerprint.

Cite this